TriangleCabozantinib (NCT05361720)
Cabozantinib trial for Advanced Clear Cell Renal Cell Carcinoma (NCT05361720). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic kidney cancer containing clear cells and no previous systemic kidney-cancer treatment. Tumor RNA testing must place them in eligible clusters.
The idea: test results assign treatment without randomization. One group receives intravenous ipilimumab plus nivolumab, followed by nivolumab maintenance. The other receives nivolumab plus daily oral cabozantinib. Immunotherapies release immune brakes; cabozantinib blocks growth and blood-supply signals. Researchers measure tumor responses to this treatment-selection approach.
This phase 2 study plans 54 patients. Brian Rini leads at Vanderbilt in Nashville; six US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.